All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2021-11-17T14:59:34.000Z

Orphan drug designation granted to zandelisib for follicular lymphoma

Nov 17, 2021
Share:

Bookmark this article

Follicular lymphoma (FL) is an indolent (or slowly progressing) B-cell lymphoma that represents 20‒30% of all non-Hodgkin lymphomas (NHL). It is most commonly diagnosed in patients >65 years of age. Although rare, FL can transform into a more aggressive type of lymphoma called diffuse large B-cell lymphoma (DLBCL).

Zandelisib is a selective inhibitor of phosphatidylinositol 3-kinase delta (PI3Kδ) and is in development as a once daily oral treatment for patients with B-cell malignancies. It is currently being evaluated in several phase II and III clinical trials:

  • The phase II TIDAL study (NCT03768505) is evaluating zandelisib as a single agent in patients with relapsed or refractory (R/R) FL and R/R marginal zone lymphoma (MZL) who have failed at least two prior systemic therapies, including chemotherapy and an anti-CD20 antibody.
  • The phase III COASTAL study (NCT04745832) is evaluating zandelisib plus rituximab in patients with R/R FL and R/R MZL who have received at least one prior line of therapy, which must have included an anti-CD20 antibody in combination with chemotherapy or lenalidomide.
  • A pivotal phase II study (NCT04533581) in Japan evaluating patients with indolent B-cell non-Hodgkin lymphoma (iNHL) without small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL), and Waldenström’s macroglobulinemia (WM).

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to zandelisib for the treatment of patients with FL. This designation, which is granted by the FDA to drugs that are intended for the treatment of a rare disease or condition (one that affects fewer than 200,000 individuals), carries incentives for the company, including tax credits, fee exemptions, and a period of market exclusivity.

  1. Business Wire. MEI Pharma and Kyowa Kirin receive orphan drug designation for zandelisib for the treatment of follicular lymphoma. https://www.businesswire.com/news/home/20211110005591/en/MEI-Pharma-and-Kyowa-Kirin-receive-Orphan-Drug-Designation-for-Zandelisib-for-the-Treatment-of-Follicular-Lymphoma. Published Nov 10, 2021. Accessed Nov 11, 2021.

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox